PatternsRadar
Sign in

MEDICAMEQMedicamen Biotech Limited

NSE
Full chart
311.95INR+3.95 (+1.28%)Close · 6 Oct 2026
14 Aug 2026Last results
—Sector
—Industry
₹423 CrMarket cap
42.1P/E (TTM)
100.0%Delivery

Filings & corporate actions

20 results filed
CSV
Next results · Q2 FY27
Expected 3 Nov 2026 – 15 Nov 2026
Estimate: filed 34–46 days after quarter end, last 5 times
Dividend
₹1.00 per share · last 18 Sept 2026
2026
  • 18 SeptdividendDividend · ₹1.00 per share-5.3%
  • 14 AugresultsResults · Q1 FY27 · consolidated and standalone-8.6%NSE
  • 16 JulshareholdingShareholding · 30 Jun 2026+0.7%NSE
  • 27 MayresultsResults · Q4 FY26 · consolidated and standalone-4.6%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
  • 13 FebresultsResults · Q3 FY26 · consolidated and standalone-4.0%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-3.1%NSE

Reaction to results · all yearsrose on day 0 in 5 of 20 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026-8.6%-2.9%+32.3%4.3×
Q4 FY2627 May 2026-4.6%-13.7%-15.2%3.7×
Q3 FY2613 Feb 2026-4.0%-14.4%-23.5%1.2×
Q2 FY2614 Nov 2025-3.5%-2.3%-3.9%1.8×
Q1 FY2612 Aug 2025-3.7%+1.1%-4.1%1.3×
Q4 FY2530 May 2025-2.3%-1.5%-2.8%2.2×
Q3 FY2511 Feb 2025-2.0%+4.8%-8.9%2.2×
Q2 FY2515 Nov 2024+0.3%-2.0%+22.8%0.3×
Q1 FY2513 Aug 2024-4.3%+2.2%+9.2%1.7×
Q4 FY2429 May 2024-4.8%-4.6%-10.3%1.1×
Q3 FY2412 Feb 2024+8.3%+15.0%-16.7%13.7×
Q2 FY2410 Nov 20230.0%-1.2%-10.1%0.2×
Q1 FY248 Aug 2023+0.9%-6.1%-14.5%1.3×
Q4 FY2331 May 2023-3.3%-2.5%+3.2%1.5×
Q3 FY2310 Feb 2023-2.7%-7.3%-16.0%0.5×
Q2 FY2311 Nov 2022-4.8%-6.7%-8.2%0.9×
Q1 FY2310 Aug 2022-0.8%+13.2%+43.6%0.9×
Q4 FY2225 May 2022+2.2%+16.6%-3.6%1.3×
Q3 FY228 Feb 2022-7.2%-16.8%-21.7%3.0×
Q2 FY223 Nov 2021+16.0%+6.3%+16.4%—
Average-1.4%-1.1%-1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+11.3%
Profit YoY+15.3%
Interest cost YoY-12.0%
Revenue QoQ-21.0%
Profit QoQ-58.5%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+6.0%+10.6%+13.8%———
Profit+25.8%-12.7%-8.5%———

Key data

CSV
Open308.00
Day range304.00 – 317.85
52-week range212.40 – 447.65
From 52w high-30.3%
RSI (14)55.2
ATR (14)19.33
Volume14.8K
Avg volume (20D)89.5K
Rel volume0.17×
Volatility (1Y)48.3%
Turnover₹46.2L
SMA 50 / 200272.06 / 286.99

Delivery percentage

Latest · 6 Oct 2026100.0%
20-day avg78.8%
1-year avg62.0%
Percentile (own history)100th
Range11.9–100.0%
Sessions1,221

Over the last 20 sessions MEDICAMEQ settled 78.8% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 62.0%, so recent sessions are running 16.8 points higher than usual. That is the highest reading in the 1,221 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Industry—
PeersMANCREDITGANESHCPDPWIRESMSPLESAFSFBHAWKINCOOK

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.28%-4.59%+20.26%+26.37%+36.24%+2.77%

Valuation

CSV
Market cap₹423 Cr
P/E (TTM)42.1
EPS (TTM)7.40
Shares outstanding1.36Cr
Listed—

Ownership

CSV
Promoter40.46%
Promoter Δ QoQ0.00 pp
Public59.54%
FII0.07%
DII0.40%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)47.246.960.647.9
YoY chg+5.4%+3.9%+104.8%+11.3%
Net profit (₹ Cr)2.11.64.41.8
YoY chg+133.9%-44.1%+138.6%+15.3%
Net margin4.5%3.5%7.3%3.9%
EPS1.561.213.281.36

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 40.46% · public 59.54%
30 Sept 2021: promoter 44.83%31 Dec 2021: promoter 43.60%31 Mar 2022: promoter 43.60%30 Jun 2022: promoter 43.60%12 Sept 2022: promoter 43.21%30 Sept 2022: promoter 43.21%31 Dec 2022: promoter 43.21%31 Mar 2023: promoter 43.21%30 Jun 2023: promoter 43.21%30 Sept 2023: promoter 43.21%31 Dec 2023: promoter 43.21%31 Mar 2024: promoter 43.21%30 Jun 2024: promoter 42.99%30 Sept 2024: promoter 42.99%31 Dec 2024: promoter 42.99%31 Mar 2025: promoter 43.16%24 Apr 2025: promoter 40.46%30 Jun 2025: promoter 40.46%30 Sept 2025: promoter 40.46%31 Dec 2025: promoter 40.46%31 Mar 2026: promoter 40.46%30 Jun 2026: promoter 40.46%
2021-092026-06
  • Promoter
  • Public and others
Promoter
40.46%
Public
59.54%
Promoter change
0.00 pp
Filed
16 Jul 2026
FII
0.07%
DII
0.40%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations43.546.547.343.044.745.129.643.047.246.960.647.9
Other income0.50.80.60.60.30.15.20.50.40.51.70.9
Total income44.147.347.943.645.045.334.843.547.547.462.448.8
Total expenses41.644.145.242.143.141.432.441.444.945.357.346.2
└ Finance costs0.90.61.90.71.00.80.61.21.01.00.40.8
└ Depreciation1.81.81.81.82.62.20.51.81.91.81.71.8
Profit before tax2.53.32.71.62.03.92.52.12.72.15.12.6
Tax expense1.01.20.60.81.11.00.60.50.60.50.60.7
Net profit1.52.02.00.80.92.91.91.62.11.64.41.8
EPS1.171.601.610.630.712.301.471.181.561.213.281.36
Net margin3.39%4.37%4.31%1.86%2.02%6.47%6.29%3.72%4.48%3.48%7.33%3.85%
PBT margin5.66%7.04%5.61%3.62%4.37%8.59%8.41%4.95%5.69%4.50%8.34%5.37%
Tax rate40.08%37.97%23.17%48.68%53.80%24.63%25.16%24.89%21.19%22.56%12.11%28.22%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

MEDICAMEQ at a glance

  • MEDICAMEQ closed at ₹311.95 on 6 Oct 2026, +1.28% on the day, +2.8% over one year, 30.3% below its 52-week high of ₹447.65.
  • Delivery was 100.0% of traded quantity on 6 Oct 2026, the 100th percentile of its own 1,221 sessions with a reading (20-session average 78.8%, 1-year average 62.0%).
  • Market capitalisation is ₹423 crore at a trailing P/E of 42.1 (trailing EPS ₹7.4).
  • Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹48 crore (+11.3% year on year), net profit ₹2 crore (+15.3%); the price moved -8.6% on the first session after.
  • Promoters held 40.46% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 3 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sector—
Basic industry—
ISININE646B01010
SeriesBE
Listed—
History from27 Oct 2021
Sessions1,225

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

Other NSE equitys by turnover

CSV